Company profile: Affinergy
1.1 - Company Overview
Company description
- Provider of application-specific coatings and medical devices for orthopedic and cardiovascular markets; diagnostic assays including an ApoL1 G0 variant blood test to inform kidney transplantation, therapeutic drug monitoring for Tacrolimus, Vancomycin and Hepcidin, and immune profile diagnostics for autoimmune diseases; plus peptide and antibody display services to identify interactions and binding affinities, and epitope mapping.
Products and services
- Immune Profile Diagnostics: Clinical-grade assays that diagnose, stratify, and reveal immune status across Scleroderma, Lupus, ALS, Multiple Sclerosis, Vasculitis, and Cardiac Sarcoidosis
- Therapeutic Drug Monitoring: Assay-grade measurements of small molecular targets Tacrolimus, Vancomycin, and Hepcidin, engineered via peptide phage display and receptor affinity maturation to quantify target concentrations
- ApoL1 Assay: High-specificity diagnostic test detecting ApoL1 G0 variant in blood to inform clinical decisions and improve kidney transplantation success through accurate variant detection
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Affinergy
ThermoGenesis
HQ: United States
Website
- Description: Provider of automated technologies for cell-based therapeutics and bioprocessing, including BioArchive for computer-controlled preservation of cells with traceability; X-LAB for rapid, closed-system mononuclear cell isolation; PXP-1000 for automated cord blood stem cell processing; 3D Bag Set for buffy coat transfer with sterile cryoprotectant addition for long-term storage; and cleanroom and wet lab facilities for life science startups.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ThermoGenesis company profile →
Idaho Molecular
HQ: United States
Website
- Description: Provider of devices that help labs, hospitals, and research facilities make data driven decisions, using biotechnology to improve human lives.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Idaho Molecular company profile →
Trinean
HQ: Belgium
Website
- Description: Provider of micro-volume molecular spectroscopy solutions, combining best-in-class analytical software with a highly standardized read-out platform; commercializes UV/VIS spectrometers.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Trinean company profile →
Teneobio
HQ: United States
Website
- Description: Provider of human heavy chain antibody discovery and development, with pre-clinical and clinical programs for multiple myeloma, prostate cancer, and immune disorders. Its antibody discovery engine is based on UniRat™.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Teneobio company profile →
StatLab
HQ: United States
Website
- Description: Provider of diagnostic supplies for the anatomic pathology lab market, developing and manufacturing cost-effective histology, cytology, and immunohistochemistry products. Offerings include large-format tissue processing cassettes, histology reagents, slides and cassettes, paraffin embedding wax, cytology collection devices, fixatives, stains, accessories, and microbiology consumables such as sterile, control, and printed diagnostic slides.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full StatLab company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Affinergy
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Affinergy
2.2 - Growth funds investing in similar companies to Affinergy
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Affinergy
4.2 - Public trading comparable groups for Affinergy
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →